Evidence map›Paper›PMID 21459141›Full record

ArticleFree radical biology & medicine2011

Comment on "Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer," i.e., all we are saying is, give C a chance.

Joseph J Cullen, Douglas R Spitz, Garry R Buettner

Open access · greenAbstract readCommentLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Free radical biology & medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Joseph J CullenFree Radical and Radiation Biology Graduate Program, Department of Surgery, The University of Iowa College of Medicine, Iowa City, IA 52242, USA. joseph-cullen@uiowa.edu
Douglas R Spitz
Garry R Buettner
University of Iowa · US

Funding

Quantitative Redox BiologyR01GM073929 · NIGMS · UNIVERSITY OF IOWA · PI BUETTNER, GARRY R · 2008 to 2011
$1.5M
The Use of 2-Deoxyglucose in Head and Neck Cancer TherapyR01CA133114 · NCI · UNIVERSITY OF IOWA · PI SPITZ, DOUGLAS ROBERT · 2009 to 2013
$1.5M
Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancerR21CA137230 · NCI · UNIVERSITY OF IOWA · PI CULLEN, JOSEPH J · 2009 to 2010
$363k
Enhancement of Cancer Therapy Using Ketogenic DietsR21CA139182 · NCI · UNIVERSITY OF IOWA · PI SPITZ, DOUGLAS ROBERT · 2009 to 2010
$363k
Role of HIF-1 alpha in EcSOD-Induced Growth Inhibition of Pancreatic CancerI01BX001318 · VA · IOWA CITY VA MEDICAL CENTER · PI CULLEN, JOSEPH J · 2013 to 2018
–
BLRD VA I01 BX001318NCI NIH HHS R01 CA133114NCI NIH HHS R01CA133114NCI NIH HHS R21 CA137230NCI NIH HHS R21CA137230NCI NIH HHS R21 CA139182NCI NIH HHS R21CA139182NIGMS NIH HHS R01 GM073929NIGMS NIH HHS R01GM073929
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdenocarcinomaAdministration, OralAnimalsAntineoplastic Combined Chemotherapy ProtocolsAscorbic AcidDeoxycytidineDrug SynergismGemcitabineHumansInjections, IntravenousMicePancreatic NeoplasmsTreatment OutcomeAscorbic AcidDeoxycytidineGemcitabine

Identifiers

PMID21459141
PMCPMC3128375
OpenAlexW2089856202

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.